Nicorandil is a potassium channel opener and nitric oxide donor (NO donor) in arteries and veins. It binds to the sulfonylurea receptors (SUR2) in the muscle cells of the blood vessels. This leads to increased ATPase activity and consequently to a reduced ATP concentration in the cell. This causes the ATP-dependent potassium channels to open and a potassium outflow occurs. The result is hyperpolarization of the muscle cells in the vessels and muscle relaxation with subsequent vasodilation. The hyperpolarization also causes voltage-dependent calcium channels to close, which leads to prolonged vasodilation. Nicorandil also releases nitric oxide, which activates guanylate cyclase. This subsequently leads to dephosphorylation of myosin, resulting in relaxation of the muscle cells.
Nicorandil is broken down via the liver and excreted via the kidneys. The bioavailability of Nicorandil, i.e. the percentage of the active substance available in the blood, is 75%. The half-life, the time the body needs to excrete half of the active substance, is one hour. The maximum plasma concentration (Cmax), i.e. the maximum concentration of the active substance in the blood plasma (liquid cell-free part of the blood), is reached after 30-60 minutes and is approx. 300 ng/ml.